HCSGD entry for EGLN1


1. General information

Official gene symbolEGLN1
Entrez ID54583
Gene full nameegl nine homolog 1 (C. elegans)
Other gene symbolsC1orf12 ECYT3 HIF-PH2 HIFPH2 HPH-2 HPH2 PHD2 SM20 ZMYND6
Links to Entrez GeneLinks to Entrez Gene

2. Neighbors in the network

color bar
This gene isn't in PPI subnetwork.

3. Gene ontology annotation

GO ID

GO term

Evidence

Category

GO:0001666Response to hypoxiaIDAbiological_process
GO:0005506Iron ion bindingIEAmolecular_function
GO:0005515Protein bindingIPImolecular_function
GO:0005634NucleusIEAcellular_component
GO:0005737CytoplasmIDAcellular_component
GO:0005829CytosolTAScellular_component
GO:0018401Peptidyl-proline hydroxylation to 4-hydroxy-L-prolineIDAbiological_process
GO:0019899Enzyme bindingISSmolecular_function
GO:0030821Negative regulation of cAMP catabolic processISSbiological_process
GO:0031418L-ascorbic acid bindingIEAmolecular_function
GO:0031543Peptidyl-proline dioxygenase activityTASmolecular_function
GO:0031545Peptidyl-proline 4-dioxygenase activityIDAmolecular_function
GO:0032364Oxygen homeostasisIDAbiological_process
GO:0043433Negative regulation of sequence-specific DNA binding transcription factor activityIDAbiological_process
GO:0045765Regulation of angiogenesisISSbiological_process
GO:0051344Negative regulation of cyclic-nucleotide phosphodiesterase activityISSbiological_process
GO:0055008Cardiac muscle tissue morphogenesisIEAbiological_process
GO:0060347Heart trabecula formationIEAbiological_process
GO:0060412Ventricular septum morphogenesisIEAbiological_process
GO:0060711Labyrinthine layer developmentIEAbiological_process
GO:0061418Regulation of transcription from RNA polymerase II promoter in response to hypoxiaTASbiological_process
GO:0071456Cellular response to hypoxiaTASbiological_process
GO:0071731Response to nitric oxideIDAbiological_process
Entries Per Page
Displaying Page of

4. Expression levels in datasets

  • Meta-analysis result

p-value upp-value downFDR upFDR down
0.07152324760.43955479280.57064668081.0000000000

  • Individual experiment result
    ( "-" represent NA in the specific microarray platform )

Data sourceUp or downLog fold change
GSE11954Down-0.4460102873
GSE13712_SHEARUp0.4586971912
GSE13712_STATICUp0.2038249399
GSE19018Up0.7613071452
GSE19899_A1Up0.2029025016
GSE19899_A2Up1.0177552642
PubMed_21979375_A1Up0.3095452979
PubMed_21979375_A2Up0.8040902707
GSE35957Down-0.4561257305
GSE36640Down-0.3577249135
GSE54402Up0.1351500193
GSE9593Up0.0865339941
GSE43922Up0.0393039226
GSE24585Down-0.0715266995
GSE37065Up0.0603624816
GSE28863_A1Up0.1135722372
GSE28863_A2Down-0.2289296563
GSE28863_A3Down-0.3618580029
GSE28863_A4Down-0.3082373221
GSE48662Up0.4126141343

5. Regulation relationships with compounds/drugs/microRNAs

  • Compounds

Compound

Target

Confidence score

Uniprot

CHEMBL90852CHEMBL56979Q9GZT9
CHEMBL520935CHEMBL56979Q9GZT9
CHEMBL222115CHEMBL56979Q9GZT9
CHEMBL221232CHEMBL56979Q9GZT9
CHEMBL90852CHEMBL56979Q9GZT9
CHEMBL220546CHEMBL56979Q9GZT9
CHEMBL51979CHEMBL56979Q9GZT9
CHEMBL218424CHEMBL56979Q9GZT9
CHEMBL221316CHEMBL56979Q9GZT9
CHEMBL376626CHEMBL56979Q9GZT9
CHEMBL569062CHEMBL56979Q9GZT9
CHEMBL221861CHEMBL56979Q9GZT9
CHEMBL218493CHEMBL56979Q9GZT9
CHEMBL218887CHEMBL56979Q9GZT9
CHEMBL220743CHEMBL56979Q9GZT9
CHEMBL316034CHEMBL56979Q9GZT9
CHEMBL220695CHEMBL56979Q9GZT9
CHEMBL90852CHEMBL56979Q9GZT9
CHEMBL503160CHEMBL56979Q9GZT9
CHEMBL218888CHEMBL56979Q9GZT9
CHEMBL485023CHEMBL56979Q9GZT9
CHEMBL90852CHEMBL56979Q9GZT9
CHEMBL218005CHEMBL56979Q9GZT9
CHEMBL480159CHEMBL56979Q9GZT9
CHEMBL221026CHEMBL56979Q9GZT9
CHEMBL90852CHEMBL56979Q9GZT9
CHEMBL518140CHEMBL56979Q9GZT9
CHEMBL221971CHEMBL56979Q9GZT9
CHEMBL441860CHEMBL56979Q9GZT9
CHEMBL222824CHEMBL56979Q9GZT9
CHEMBL1686CHEMBL56979Q9GZT9
CHEMBL90852CHEMBL56979Q9GZT9
CHEMBL375008CHEMBL56979Q9GZT9
CHEMBL218481CHEMBL56979Q9GZT9
CHEMBL221604CHEMBL56979Q9GZT9
CHEMBL568873CHEMBL56979Q9GZT9
CHEMBL220796CHEMBL56979Q9GZT9
CHEMBL453519CHEMBL56979Q9GZT9
CHEMBL217944CHEMBL56979Q9GZT9
CHEMBL218015CHEMBL56979Q9GZT9
CHEMBL1686CHEMBL56979Q9GZT9
CHEMBL218070CHEMBL56979Q9GZT9
CHEMBL218233CHEMBL56979Q9GZT9
CHEMBL222009CHEMBL56979Q9GZT9
CHEMBL449035CHEMBL56979Q9GZT9
CHEMBL485023CHEMBL56979Q9GZT9
CHEMBL569062CHEMBL56979Q9GZT9
CHEMBL221025CHEMBL56979Q9GZT9
CHEMBL218480CHEMBL56979Q9GZT9
CHEMBL517834CHEMBL56979Q9GZT9
CHEMBL221341CHEMBL56979Q9GZT9
CHEMBL217945CHEMBL56979Q9GZT9
CHEMBL374866CHEMBL56979Q9GZT9
CHEMBL1686CHEMBL56979Q9GZT9
CHEMBL479415CHEMBL56979Q9GZT9
CHEMBL485022CHEMBL56979Q9GZT9
CHEMBL220659CHEMBL56979Q9GZT9
CHEMBL221241CHEMBL56979Q9GZT9
CHEMBL268057CHEMBL56979Q9GZT9
CHEMBL218288CHEMBL56979Q9GZT9
CHEMBL576CHEMBL56979Q9GZT9
CHEMBL222114CHEMBL56979Q9GZT9
CHEMBL576CHEMBL56979Q9GZT9
CHEMBL447601CHEMBL56979Q9GZT9
CHEMBL570655CHEMBL56979Q9GZT9
CHEMBL218482CHEMBL56979Q9GZT9
CHEMBL481692CHEMBL56979Q9GZT9
CHEMBL374946CHEMBL56979Q9GZT9
CHEMBL90852CHEMBL56979Q9GZT9
CHEMBL427234CHEMBL56979Q9GZT9
CHEMBL269093CHEMBL56979Q9GZT9
CHEMBL501554CHEMBL56979Q9GZT9
CHEMBL481875CHEMBL56979Q9GZT9
CHEMBL518141CHEMBL56979Q9GZT9
CHEMBL1686CHEMBL56979Q9GZT9
CHEMBL387428CHEMBL56979Q9GZT9
CHEMBL221012CHEMBL56979Q9GZT9
CHEMBL221970CHEMBL56979Q9GZT9
CHEMBL386421CHEMBL56979Q9GZT9
CHEMBL384018CHEMBL56979Q9GZT9
CHEMBL90852CHEMBL56979Q9GZT9
CHEMBL217943CHEMBL56979Q9GZT9
CHEMBL481700CHEMBL56979Q9GZT9
CHEMBL1686CHEMBL56979Q9GZT9
CHEMBL426560CHEMBL56979Q9GZT9
CHEMBL426560CHEMBL56979Q9GZT9
CHEMBL509126CHEMBL56979Q9GZT9
CHEMBL384996CHEMBL56979Q9GZT9
CHEMBL480160CHEMBL56979Q9GZT9
CHEMBL519615CHEMBL56979Q9GZT9
CHEMBL221974CHEMBL56979Q9GZT9
CHEMBL221013CHEMBL56979Q9GZT9
CHEMBL445510CHEMBL56979Q9GZT9
CHEMBL220498CHEMBL56979Q9GZT9
CHEMBL221189CHEMBL56979Q9GZT9
CHEMBL316034CHEMBL56979Q9GZT9
CHEMBL568873CHEMBL56979Q9GZT9
CHEMBL221919CHEMBL56979Q9GZT9
CHEMBL374147CHEMBL56979Q9GZT9
CHEMBL90852CHEMBL56979Q9GZT9
CHEMBL572739CHEMBL56979Q9GZT9
CHEMBL221027CHEMBL56979Q9GZT9
CHEMBL222010CHEMBL56979Q9GZT9
CHEMBL221918CHEMBL56979Q9GZT9
CHEMBL387429CHEMBL56979Q9GZT9
CHEMBL447994CHEMBL56979Q9GZT9
CHEMBL89286CHEMBL56979Q9GZT9
CHEMBL1435274CHEMBL56978Q9GZT9
CHEMBL90852CHEMBL56978Q9GZT9
CHEMBL522970CHEMBL56978Q9GZT9
CHEMBL1800368CHEMBL56978Q9GZT9
CHEMBL521790CHEMBL56978Q9GZT9
CHEMBL1938900CHEMBL56978Q9GZT9
CHEMBL491424CHEMBL56978Q9GZT9
CHEMBL78920CHEMBL56978Q9GZT9
CHEMBL448208CHEMBL56978Q9GZT9
CHEMBL503507CHEMBL56978Q9GZT9
CHEMBL448608CHEMBL56978Q9GZT9
CHEMBL489155CHEMBL56978Q9GZT9
CHEMBL491426CHEMBL56978Q9GZT9
CHEMBL491425CHEMBL56978Q9GZT9
CHEMBL522419CHEMBL56978Q9GZT9
CHEMBL509064CHEMBL56978Q9GZT9
Entries Per Page
Displaying Page of

  • Drugs

Name

Drug

Accession number

Vitamin CDB00126 NUTR00001 | APRD00084 | EXPT00568 | DB09541
FG-4592DB04847 -
N-[(4-HYDROXY-8-IODOISOQUINOLIN-3-YL)CARBONYL]GLYCINEDB07112 -
N-[(1-CHLORO-4-HYDROXYISOQUINOLIN-3-YL)CARBONYL]GLYCINEDB08687 -

  • MicroRNAs

    • mirTarBase

MiRNA_name

mirBase ID

miRTarBase ID

Experiment

Support type

References (Pubmed ID)

hsa-miR-335-5pMIMAT0000765MIRT016815MicroarrayFunctional MTI (Weak)18185580
hsa-miR-296-3pMIMAT0004679MIRT038498CLASHFunctional MTI (Weak)23622248
Entries Per Page
Displaying Page of
    • mirRecord
No target information from mirRecord

6. Text-mining results about the gene

Gene occurances in abstracts of cellular senescence-associated articles: 2 abstracts the gene occurs.


PubMed ID of the article

Sentenece the gene occurs

21746877Additionally, we found that cyclin E deregulation in mammary acini decreases, in an E2F-independent manner, expression of the EGLN1 prolyl hydroxylase that regulates HIF-1alpha degradation within the VHL ubiquitin ligase pathway
16161047Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1
16161047Introduction of wild-type EGLN1 into endometrial cancer cell lines (HHUA, Ishikawa and HWCA), that carry EGLN1 gene mutations induced senescence
16161047Thus, EGLN1 can be considered as a candidate tumor suppressor on chr
16161047These results also suggested the availability of negative regulation of HIF-1 signals for uterine cancer treatment, especially for uterine sarcomas that have worse prognosis and show a high frequency of EGLN1 gene abnormality
Entries Per Page
Displaying Page of